Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.420
+0.010 (0.71%)
At close: May 2, 2025, 4:00 PM
1.490
+0.070 (4.93%)
Pre-market: May 5, 2025, 4:11 AM EDT
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$32,286
Profits / Employee
-$7,810,571
Market Cap
7.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TRAW News
- 4 weeks ago - Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript - Seeking Alpha
- 5 weeks ago - Traws Pharma Announces Management Updates - GlobeNewsWire
- 5 weeks ago - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - GlobeNewsWire
- 5 weeks ago - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewsWire
- 6 weeks ago - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewsWire
- 2 months ago - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 2 months ago - Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule - GlobeNewsWire
- 3 months ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire